Navigation Links
ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Date:12/11/2007

LEUVEN, Belgium, December 11 /PRNewswire-FirstCall/ --

- TB-402 Shows Clear Promise as a Stable Long-acting Anticoagulant for the Prevention of Thromboembolic Disorders.

ThromboGenics NV (Euronext Brussels:THR), a biotechnology company focused on vascular and eye disease, announced that the results of the first Phase I trial of TB-402 were presented yesterday at the prestigious American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, Georgia, USA. TB-402 is being co-developed in collaboration with BioInvent International (Nordic Exchange: BINV).

TB-402 is a recombinant human monoclonal antibody which has shown a beneficial partial inhibition of the blood coagulation Factor VIII. Its long half life of approximately three weeks enables it to produce a stable and long-acting inhibition. This indicates well-controlled inhibition of Factor VIII activity with low risk of spontaneous bleeding, thus avoiding the possibility of overdose and the need for patient monitoring.

These unique features may be of major clinical significance, as it suggests that a product with an excellent safety profile, with ease of administration and compliance superior to alternative anticoagulants, can be developed. The preliminary results of the initial Phase I study were previously communicated in a Press Release issued September 7, 2007.

The Phase I trial presented at ASH was a randomized, single-dose, placebo-controlled, dose escalation trial in healthy male volunteers. 56 subjects were enrolled into the trial, including both younger age (18-45) and older age (55-76) volunteers. Results of the trial show that TB-402 is both safe and well-tolerated. No serious adverse events related to TB-402 were reported. In addition, there were no major bleeding complications, with the overall incidence being similar in both the TB-402 treated group and the patients who received placebo.

The pharmacokinetic analysis undertaken as part of the study
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...Nov. 5 Cepheid (Nasdaq: ...e speaking at the following investor conferences, ..., , Credit Suisse Healthcare Confe...ovember, 2009 at 10 a.m. Mountain Time, ...ngland, Tuesday, 1 December, 2009 ...
(Date:11/5/2009)...mber 5, 2009 Senomyx, In...oprietary taste receptor-based technologies to dis...age, and ingredient supply industries, today provi...lts for the third quarter ended September 30, 2009...r of 2009, compared to $4.0 million for the third ...
(Date:11/5/2009)... 5 SpineSmith Partners has signed ...elop a unique scaffold that mimics the structure o...f several commercial products by SpineSmith,s Rese...ves the GenOsteo scaffold represents a significant...nd ideal environment for the delivery of adult ste...
(Date:11/5/2009)... Drug safety specialty firm BioSoteria announced t...s earned the Certified Professional in Learning an...erican Society for Training and Development (ASTD)...re than fifteen years of medical communications an...le for the development of the company,s online pha...
Breaking Biology Technology:Cepheid to Webcast Upcoming Financial Presentations 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4
...cs,Inc. (Nasdaq: CVTX ) announced today that new ...ege of Cardiology Foundation and the American Hear...f Circulation, state that,"ranolazine may be safel..." Ranexa(R) (ranolazine extended-release tablets)...in patients who have not achieved an adequate,resp...
...tt,Limited (Nasdaq: WCRX ) announced today that i... from Barr Laboratories, Inc. ("Barr") advising th... Application (ANDA) for a,generic version of FEMCO...any during the second half,of 2006, is a chewable ...,No. 6,667,050 which expires in 2019. The Company...
...Engineering Microbes to Produce Lower Cost Anti-... TR35 2007 Recipients to be Honored at Technology...s Conference at MIT, EMERYVILLE, Calif., Aug. 15 ...t Neil Renninger, Ph.D., co-founder and senior vic... Technology Review magazine,as one of the world,s ...
Other Biology Technology:Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI) 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 3Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 2Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 3
(Date:11/3/2009)...s greatest wines are the result of a threefold syn...ng called the "terroir" -- a term often defined as...ts will discuss terroir with an emphasis on soil s...sburgh. "Terroir: Winegrapes and the Environment"... Meetings of the American Society of Agronomy (ASA...
(Date:11/3/2009)...the ocean, cruising thousands of miles in a solita...that the sharks have maintained such a consistent ...f years the white sharks in the northeastern Pacif...on genetically distinct from sharks elsewhere in t...bile species," said Salvador Jorgensen, a postdoct...
(Date:11/3/2009)...d vegetables is a new, patented technology in whic...o label, or "etch" information on produce, thereby...ls. The technology has been licensed for use on a ... in New Zealand, Australia, and Pacific Rim countr...ca, Central and South America, Canada, and the Eur...
Breaking Biology News(10 mins):Great wines come from great soils 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4Laser etching safe alternative for labeling grapefruit 2FDA Advisers Urge Smaller Doses of Acetaminophen 50458 1FDA Advisers Urge Smaller Doses of Acetaminophen 50458 2FDA Advisers Urge Smaller Doses of Acetaminophen 50458 3FDA Advisers Recommend Smaller Doses of Acetaminophen 50455 1FDA Advisers Recommend Smaller Doses of Acetaminophen 50455 2More than One Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 50452 1More than One Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 50452 2More than One Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 50452 3
..."color-blind" method of fluorescence detection dev...e (BCM) and Rice University could open new doors t...side, the doctor,s office and even the scene of a ...direct detection of a DNA sequence from native DNA...tory, said Dr. Michael L. Metzker, assistant profe...
...molecule designed to block cat allergies successfu...e, as well as in human cells in a test tube, Unive...s report in the April issue of Nature Medicine, av...rs say, these promising results could lead to a ne...so possibly for severe food allergies such as thos...
...e crystallized form of a molecular machine that ca...ible new paths for treating diseases such as some ...plague HIV patients. , Purdue University research...re chemical complexes known as a Group I intron, a...llized introns reveal their structure and the site...
Other Biology News:Color-blind method opens new doors in DNA sequencing 2Color-blind method opens new doors in DNA sequencing 3Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Molecular machine may lead to new drugs to combat human diseases 2Molecular machine may lead to new drugs to combat human diseases 3
...cally collected via cardiac puncture from 3 to 4 w... is then centrifuged and frozen at -70C. The compl...led at 4C then stored at -70C. DIRECT SALES FROM P...FREEZ COMPLEMENT, YOU CAN NOW BUY DIRECTLY FROM TH...
Thermal Grayscale USB Printer for Imaging Systems; USB Connection from Alpha Innotech
GIBCO Newborn Calf Serum Heat-Inactivated from Invitrogen
Ready-To-Use IHC Bluing Reagent from Bethyl Laboratories
Biology Products: